258 related articles for article (PubMed ID: 20923917)
1. Mortality in schizophrenia: a measurable clinical endpoint.
Bushe CJ; Taylor M; Haukka J
J Psychopharmacol; 2010 Nov; 24(4 Suppl):17-25. PubMed ID: 20923917
[TBL] [Abstract][Full Text] [Related]
2. Influence of antipsychotics on mortality in schizophrenia: systematic review.
Weinmann S; Read J; Aderhold V
Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.
Kelly DL; McMahon RP; Liu F; Love RC; Wehring HJ; Shim JC; Warren KR; Conley RR
J Clin Psychiatry; 2010 Mar; 71(3):304-11. PubMed ID: 20079332
[TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
5. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
De Hert M; Correll CU; Cohen D
Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
[TBL] [Abstract][Full Text] [Related]
6. [Schizophrenia, diabetes mellitus and antipsychotics].
Gury C
Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.
Curkendall SM; Mo J; Glasser DB; Rose Stang M; Jones JK
J Clin Psychiatry; 2004 May; 65(5):715-20. PubMed ID: 15163261
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
9. Life expectancy and cardiovascular mortality in persons with schizophrenia.
Laursen TM; Munk-Olsen T; Vestergaard M
Curr Opin Psychiatry; 2012 Mar; 25(2):83-8. PubMed ID: 22249081
[TBL] [Abstract][Full Text] [Related]
10. Mortality in schizophrenia.
Auquier P; Lançon C; Rouillon F; Lader M; Holmes C
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):873-9. PubMed ID: 17058327
[TBL] [Abstract][Full Text] [Related]
11. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
[TBL] [Abstract][Full Text] [Related]
12. Viewpoint: do antipsychotics protect against early death? A critical view.
Whitaker R
Psychol Med; 2020 Dec; 50(16):2643-2652. PubMed ID: 33050955
[TBL] [Abstract][Full Text] [Related]
13. Serious cardiovascular events and mortality among patients with schizophrenia.
Enger C; Weatherby L; Reynolds RF; Glasser DB; Walker AM
J Nerv Ment Dis; 2004 Jan; 192(1):19-27. PubMed ID: 14718772
[TBL] [Abstract][Full Text] [Related]
14. [Leponex, 10 years after -- a clinical review].
Llorca PM; Pere JJ
Encephale; 2004; 30(5):474-91. PubMed ID: 15627052
[TBL] [Abstract][Full Text] [Related]
15. Causes of premature mortality in schizophrenia: a review of literature published in 2018.
Laursen TM
Curr Opin Psychiatry; 2019 Sep; 32(5):388-393. PubMed ID: 31135491
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.
Montout C; Casadebaig F; Lagnaoui R; Verdoux H; Philippe A; Begaud B; Moore N
Schizophr Res; 2002 Oct; 57(2-3):147-56. PubMed ID: 12223245
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
18. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.
Khan A; Schwartz K; Stern C; Redding N; Kolts RL; Brown WA; Robinson DS
J Clin Psychiatry; 2007 Dec; 68(12):1828-33. PubMed ID: 18162012
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
20. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
Ward A; Ishak K; Proskorovsky I; Caro J
Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
